Articles tagged with Mesothelioma
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
The KIR-CAR T cell therapy has shown promising results in a Phase I clinical trial, demonstrating safety and increasing efficacy with higher doses. The treatment targets mesothelin, widely expressed on several solid tumor cancers, and limits side effects through its natural 'on-off' mechanism.
Researchers found no association between occupational talc exposure and increased risk of lung cancer, mesothelioma, or laryngeal cancer when talc is free from asbestos contamination. The study suggests continued monitoring of occupational groups to better understand any potential low-level risks.
Researchers have uncovered how BAP1 functions at the molecular level and present a novel therapeutic strategy to slow cancer progression. BAP1's role in DNA repair pathways and its potential as a biomarker for personalized treatment are also explored.
A new Mount Sinai study strengthens landmark evidence supporting lung-sparing surgery for pleural mesothelioma, a rare and aggressive cancer caused by asbestos exposure. The research found zero in-hospital and 30-day mortality rates, and a 90-day mortality rate of 4.2 percent in carefully selected patients.
Scientists at Wake Forest University School of Medicine have discovered a new way to kill cancer cells by blocking their ability to clean up harmful waste. By inhibiting peroxiredoxin-3, researchers found that toxic levels of hydrogen peroxide overwhelm cancer cells, destroying them.
The VT3989 trial demonstrated a disease control rate of 86% in refractory mesothelioma patients, with notable partial responses and stable disease. The YAP-TEAD inhibitor also showed an encouraging safety profile, supporting continued clinical development in this unmet clinical need.
Researchers found a new variant of mesothelioma associated with inherited germline BAP1 mutations, which are less aggressive and may respond to therapy. These patients also develop multiple tumors and require early cancer detection screening.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
This study investigates the use of carbonic anhydrase IX (CAIX) as a diagnostic marker for distinguishing pleural mesothelioma from non-small cell lung carcinoma (NSCLC). CAIX expression is found to be highly sensitive and specific in detecting pleural epithelioid mesothelioma, comparable to or better than existing mesothelial markers.
A University of Leicester study has found that certain gut bacteria may influence whether a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer. Researchers suggest that dietary changes, such as increased fibre intake, could improve the benefits of immunotherapy for these patients.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
This research perspective reviews the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma. The study identifies potential targets for prevention, including inflammatory factors and novel chemoprevention agents.
The study compared FDG-PET/CT and CT for evaluating treatment response in unresectable malignant pleural mesothelioma patients. The results showed that both imaging modalities provided accurate findings for tumor response evaluation, with high concordance between the two methods.
A new treatment combining a novel drug with traditional chemotherapy has been shown to increase the survival of patients with malignant mesothelioma, a rare and aggressive cancer. The ATOMIC-meso trial found that this treatment quadrupled the survival at 36 months compared to placebo-chemotherapy.
A study published in Journal of Thoracic Oncology found that Australian patients with mesothelioma experienced higher levels of toxicity on the CheckMate743 regimen compared to clinical trial results. The study suggests combination immunotherapy may have poorer survival outcomes and appears more toxic in real-world practice.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
Researchers at Sylvester Comprehensive Cancer Center found that mesothelioma patients with timely treatment and access to specialized care have better outcomes. However, disparities in access to care are evident, with Black patients being 80% more likely to die than white patients.
A study found that BRCA1 mutations increase the risk of malignant mesothelioma caused by asbestos exposure. People with this genetic defect are more susceptible to tumor growth due to impaired ferroptosis defense mechanisms.
Researchers at Rice University have developed a new fluorescent dye that can cross the blood-brain barrier, allowing for noninvasive brain imaging and differentiation between healthy tissue and tumor cells. The dye's long-lasting fluorescence enables stable imaging over extended periods.
Researchers at Baylor College of Medicine found that treating patients with resectable malignant pleural mesothelioma with immunotherapy ahead of surgery resulted in significant changes to the tumor microenvironment and increased overall survival. The study's findings provide a groundwork for neoadjuvant immunotherapy in mesothelioma.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
Researchers at CU Anschutz Medical Campus discovered a reactivated protein, Hand2, in certain cases of mesothelioma, which may lead to new treatments. The study aims to investigate the cause and effect of this reactivation.
The study reveals that asbestos minerals undergo changes that resemble self-defense when internalized by human lung cells. These changes include the formation of an iron-rich layer on the minerals, which may be a mechanism to protect the cell from toxicity.
A phase 2 clinical trial shows durvalumab immunotherapy combined with standard chemotherapy significantly improved overall survival for patients with previously untreated malignant pleural mesothlioma. The study's findings provide insights into patient selection methods for this novel chemo-immunotherapy regimen.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.
Researchers estimated a significant increase in global mesothelioma cases and deaths from 1990 to 2017. The study found that asbestos exposure remains a well-established risk factor for the disease.
Researchers at University Health Network found that combining immune-boosting drugs with radiation and surgery increased survival and anticancer immune response in mouse models of mesothelioma. The treatment extended survival and provided a durable immune response, even after re-injection of tumour cells up to 12 weeks later.
Researchers have developed an AI system to analyze DNA-sequenced mesotheliomas, revealing similar evolutionary paths that predict aggressiveness and possible therapy. This breakthrough could lead to improved patient outcomes for those with this aggressive form of cancer.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.
A recent analysis found that nearly 15% of talc-based cosmetics products contain asbestos, a deadly human carcinogen. The study highlights the need for rigorous testing methods and safer regulations to protect consumers from potential harm.
A clinical trial is underway to test the safety and feasibility of intrapleural liposomal curcumins as an alternative to chemotherapy for malignant mesothelioma. The researchers aim to reduce toxic side-effects and facilitate early diagnosis with a special lung fluid test.
Researchers have developed a form of gold nanotubes that can target and kill mesothelioma cancer cells using light. The nanotubes are made in a two-step process and have physical properties that can be tailored for enhanced therapies.
A new treatment combination of immunotherapy and chemotherapy has been shown to improve overall survival by 20.4 months in patients with inoperable malignant pleural mesothelioma, exceeding the expected survival time of 12 months with chemotherapy alone.
A phase 2 trial found that adding durvalumab to chemotherapy significantly improved median overall survival in malignant pleural mesothelioma patients, with response rates and tolerability seen as well-tolerated. The combination is considered suitable for further investigation in a randomized phase 3 study.
Researchers at CNIO have identified a potential effective treatment for sarcomatoid mesothelioma, the most aggressive type of asbestos cancer, using two existing drugs in combination. The study found that blocking MEK and PI3K pathways reduces the growth and invasiveness of mesothelioma cells in mice.
Researchers analyzed pleural effusion fluid from patients with non-small cell lung cancer and malignant mesothelioma, discovering unique cytokine profiles that may influence the tumor environment. The study suggests harnessing the local pleural immune environment could lead to improved treatment outcomes.
Researchers analyzed pleural effusions from NSCLC patients, mesothelioma, and benign cases, identifying distinct cytokine levels that may influence tumor growth and immune response. The study suggests modifying the local pleural immune environment with antibody-based therapeutics could enhance anti-tumor effects.
A recent study presented at the ESMO Congress 2019 found that nearly four times more patients responded to immunotherapy with pembrolizumab than standard chemotherapy in a trial for advanced mesothelioma. However, these responses did not delay progression or improve survival rates.
Research presented at ESTRO 38 conference finds that high dose radiation therapy significantly improves two-year survival rates for mesothelioma patients. The study, led by Dr. Marco Trovo, suggests radical hemi-thoracic radiotherapy as a new standard of care for this rare and aggressive cancer.
A mesothelin-targeted CAR T-cell therapy demonstrated antitumor activity and acceptable toxicity in a phase I clinical trial for patients with malignant pleural disease. The therapy showed significant tumor regression and reduced mesothelin-related peptide levels in the blood.
Researchers at Massachusetts General Hospital report promising preclinical results against uniformly fatal tumor, finding that combining two cancer immunotherapy drugs significantly prolongs survival time. The treatment changes a population of immunosuppressive T cells into a type that could enhance an antitumor immune response.
Researchers discovered that certain carbon nanotubes can induce mesothelioma in mice, a type of cancer linked to asbestos. The study highlights the potential carcinogenic effects of long and thin carbon nanotubes, emphasizing the need for safer alternatives.
A landmark study published in The Lancet Public Health has found a link between living in houses with loose-fill asbestos insulation and an increased risk of mesothelioma and colorectal cancer. Men were 2.5 times more likely to develop mesothelioma, while rates of colorectal cancer were higher in both men and women who had lived in con...
Researchers at Brigham and Women's Hospital discovered a rare genetic mutation in the ALK gene that causes peritoneal mesothelioma in young women with no history of asbestos or radiation therapy. Targeted therapy using FDA-approved drugs may be effective in treating these patients.
Early research suggests that immunotherapy may provide new hope to patients with relapsed mesothelioma. A phase II clinical trial found that the combination of nivolumab and ipilimumab slowed cancer growth by 44% and tumor shrinkage in 26% of patients.
Scientists at Ruhr-University Bochum have established a new process for identifying biomarkers in cancer diagnosis, utilizing infrared spectroscopy. The method enables precise analysis of protein changes in tumor tissue, facilitating personalized therapy.
Researchers have found that pembrolizumab, an immunotherapy drug, can effectively treat malignant pleural mesothelioma, a disease primarily caused by asbestos inhalation. The study, led by Evan Alley, showed promising results with tumor reduction and improved overall survival in patients.
A new study found a significant association between asbestos exposure and malignant mesothelioma in Eastern China. The research also highlights a notable difference in the male-to-female ratio of patients with mesothelioma, with more females affected than males.
A study by Loyola Medicine found that mesothelioma surgery, specifically pleurectomy and decortication, improves quality of life in patients. The procedure can control fluid buildup, improve breathing, and reduce cancer pain, with benefits observed as early as one month after surgery.
Researchers will test a nanoghost technology to deliver microRNAs targeting metastatic melanoma, while investigating heparanase for mesothelioma diagnosis and treatment. The partnership aims to advance global collaboration in cancer research and therapeutics.
A phase Ib trial demonstrated that combining immunotherapy with live bacterium CRS-207 and chemotherapy resulted in a 94% disease control rate and 59% response rate in patients with malignant pleural mesothelioma. The therapy also showed good immune activation and synergistic efficacy with chemotherapy.
Researchers have discovered a new drug, HRX9, that targets the HOX gene family and induces apoptosis in mesothelioma cells. The study found that treatment with HRX9 resulted in complete loss of tumor blood vessels and widespread cancer cell death, offering new hope for patients.
Scientists have identified a spectrum of genetic alterations, including some that may be clinically actionable and others that could improve diagnostics and screening for patients. The study's findings suggest targeted therapies and immunotherapies could be effective treatments for mesothelioma.
Researchers developed a new test that detected mesothelioma 4-10 years before symptoms appeared, using a specific protein marker. The ONCOblot test detected the ENOX2 protein in serum samples from asbestos-exposed individuals, paving the way for earlier cancer detection and potentially reducing deaths.
Researchers suggest significant improvements in mesothelioma staging by incorporating tumor weight and volume into the current TNM system. This could lead to more accurate prognoses and personalized treatment plans for patients.
Researchers at the University of Hawai'i Cancer Center found that aspirin can inhibit the growth of mesothelioma by blocking HMGB1. This could lead to improved survival rates for patients with this aggressive cancer, which kills around 3,200 people annually.
In the ATREUS trial, 41.2% of patients treated with trabectedin in second line showed improved survival and median progression-free survival at 12 weeks. The study adds to scarce evidence-based science in this disease, warranting further investigation.
A new study from the University of Pennsylvania School of Medicine found that pembrolizumab, a PD-1 inhibitor, shrank or stabilized tumors in most patients with pleural mesothelioma. The medication was safe and showed promise for treating this rare and deadly form of cancer.